Abstract | RATIONALE: OBJECTIVES: METHODS: In human and mouse studies, we infused macronutrients and manipulated glucagon availability up and down to investigate its acute and chronic metabolic role during critical illness. MEASUREMENTS AND MAIN RESULTS: CONCLUSIONS: These data suggest that elevated glucagon availability during critical illness increases hepatic amino acid catabolism, explaining the illness-induced hypoaminoacidemia, without affecting muscle wasting and without a sustained impact on blood glucose. Furthermore, amino acid infusion likely results in a further breakdown of amino acids in the liver, mediated by increased glucagon, without preventing muscle wasting. Clinical trial registered with www.clinicaltrials.gov (NCT 00512122).
|
Authors | Steven E Thiessen, Sarah Derde, Inge Derese, Thomas Dufour, Chloé Albert Vega, Lies Langouche, Chloë Goossens, Nele Peersman, Pieter Vermeersch, Sarah Vander Perre, Jens J Holst, Pieter J Wouters, Ilse Vanhorebeek, Greet Van den Berghe |
Journal | American journal of respiratory and critical care medicine
(Am J Respir Crit Care Med)
Vol. 196
Issue 9
Pg. 1131-1143
(11 01 2017)
ISSN: 1535-4970 [Electronic] United States |
PMID | 28475354
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Amino Acids
- Blood Glucose
- Insulin
- Glucagon
- Glucose
|
Topics |
- Aged
- Amino Acids
(blood)
- Animals
- Blood Glucose
- Critical Illness
- Disease Models, Animal
- Female
- Glucagon
(blood, metabolism)
- Glucose
(administration & dosage)
- Humans
- Insulin
(administration & dosage, blood)
- Male
- Mice
- Middle Aged
- Muscular Atrophy
(blood, metabolism, therapy)
- Parenteral Nutrition
(methods)
- Treatment Outcome
|